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Mycobacterium celatum has been shown to cause disease
in immunocompromised patients. We report a case of serious
pulmonary infection caused by M. celatum in an apparently
immunocompetent patient and review the characteristics of two
other reported cases. Clinical and radiologic symptoms and
signs included cough, malaise, and weight loss associated with
cavitary lesions and pulmonary infiltrates. Although M. celatum
is easy to detect in clinical specimens by liquid and solid media,
it may be misidentified as a member of the M. tuberculosis com-
plex or as M. xenopi. M. celatum pulmonary infection appears
to respond to antimycobacterial chemotherapy, particularly with
clarithromycin. 
M
ycobacterium celatum was first described in 1993 as a
new species whose mycolic acid pattern closely resem-
bled that of M. xenopi (xenopi-like) but was biochemically
indistinguishable from M. avium complex (MAC) (1). By
sequencing studies of the 16S rRNA gene, now known to exist
in two different copies within M. celatum genome (2), three dif-
ferent types could be differentiated (1,3). Cross-reactivity with
the Accuprobe assay (Gen-Probe Inc., San Diego, CA) for the
M. tuberculosis complex (MTB) was observed by probing
types 1 and 3 but not type 2 (3,4). DNAsequencing showed that
M. celatum type 1 differs by one nucleotide from the probe
used in the Accuprobe assay, type 2 differs by four nucleotides
(5), and the type 3 DNA sequence for the probe region is
unknown.
Although M. celatum has been reported to cause infection
mainly in AIDS patients (6–10), recently a growing amount of
clinical evidence indicates that the infection can lead to serious
disease in immunocompetent subjects as well (11–13). In this
case, the principles for diagnosis of diseases caused by nontu-
berculous mycobacteria, recently updated by the American
Thoracic Society (14), need to be properly followed. We report
a well-documented case of a pulmonary disease with this
mycobacterium in an apparently immunocompetent woman
and review the characteristics of two similar published cases.
The Study
A 63-year-old, HIV-negative woman was referred in June
2000 by a general practitioner to the outpatient pulmonary
service because she had exhibited a fever and night sweats for
3 months. The patient’s medical history included a mild hyper-
tensive cardiovascular disease and a pulmonary tuberculosis
episode when she was 16 years old. Her father and brother had
pulmonary tuberculosis. She lived in an urban area and had no
history of alcoholism, smoking, or use of steroids or immuno-
suppressive drugs. No other pulmonary diseases that could
potentially lead to bronchiectasis and further mycobacterial
colonization were reported. Physical examination revealed no
pathologic findings except a strong positive reaction (24 mm of
induration) with tuberculin skin test (5 U of purified protein
derivative–standard [PPD-S]). Results of clinical laboratory
tests were unremarkable, apart from an elevated erythrocyte
sedimentation rate (77 mm/h). A computed tomographic (CT)
scan of the chest showed multifocal bronchiectases in the mid-
dle right lobe, multiple small nodules in the lower right lobe,
and a cavitary lesion in the upper right lobe, which appeared to
have thin walls and was surrounded by a scant or absent inflam-
matory reaction. Bronchoscopy showed no inflammatory
mucosal changes on the right side. Smears of bronchial wash-
ing were negative for acid-fast bacilli (AFB), and smears of
two sputum specimens were positive, while all specimens gave
negative results when tested by a ligase chain reaction commer-
cial assay specific for MTB. A reactivation of tuberculosis was
assumed, and chemotherapy with isoniazid, rifampin, and
ethambutol was begun. Cultures of bronchial washing and spu-
tum specimens produced a slow-growing Mycobacterium,
which was identified as M. celatum in July 2000. The isolate
was not considered clinically important, and chemotherapy was
unchanged.
In December 2000, although the general condition of the
patient had slightly improved after 6 months of treatment, a
control CT scan showed a worsening (enlargement) of the
nodular lesions. Smears of two sputum specimens and one
bronchial washing specimen were positive for AFB, whereas
all specimens were negative when tested by the MTB ligase
chain reaction assay. All of these specimens yielded M. cela-
tum. On the basis of susceptibility data obtained from the first
M. celatum isolate, chemotherapy was changed to a schedule
that included isoniazid, ethambutol, and clarithromycin, which
lasted until November 2001. This regimen proved to be well
tolerated by the patient. The bacteriologic results (specimens
from two additional bronchial washings were negative for AFB
by smear and culture) and clinical response were good. In
December 2001, chest x-ray examinations and a CT scan
showed a considerable reduction of nodular lesions as well as
improvement of lung cavitation (Figure). The patient was con-
sidered cured after taking medication for approximately 18
months.
Clinical, microbiologic, and radiologic data as well, as
information on response to treatment and follow-up, were
obtained from the patient’s records. All material was carefully
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We examined sputum and bronchoaspirate specimens for
acid-fast organisms. They were stained with routine Ziehl-
Neelsen stain and cultured by standard procedures (15) by
using a combination of radiometric Bactec system (Becton
Dickinson Biosciences, Sparks, MD) and Löwenstein-Jensen
medium. Amplification for MTB was performed by the LCx-
MTB assay (Abbott, Diagnostics Division, Chicago, IL).
Conventional identification and growth tests were performed
according to standard methods (15). We tested recovered
strains with the Accuprobe system using specific probes for
MAC and MTB. Assays were run from liquid culture setting
the unbound probe hydrolysis incubation time at 5 and 10 min
and temperature at 60° ± 1°C (16). The amount of chemilumi-
nescence emitted was estimated with a Leader 50 luminometer
(Gen-Probe Inc., San Diego, CA, USA) and quantified as rela-
tive light units (RLUs). Definitive identification was achieved
by mycolic acids high-performance liquid chromatography
(HPLC) analysis (17). Drug susceptibility pattern was deter-
mined in 12B liquid medium (Becton Dickinson Biosciences)
by using the radiometric macrodilution method developed for
MAC (18). 
Six isolates were recovered in a 6-month period. M. cela-
tum was isolated from different specimens: two isolates were
from bronchial washing and four from sputum. Acid-fast
smears were positive in five of the six specimens. Cultures on
Löwenstein-Jensen medium yielded multiple colonies, ranging
from 100–150 CFU to a confluent growth. No additional
microorganisms were isolated during the admission and fol-
low-up period. Amplification tests performed on all respiratory
specimens were repeatedly negative for MTB on smear sam-
ples positive and negative for M. celatum. M. celatum strains
were isolated on both currently used media, radiometric liquid
medium (Bactec 12B) and conventional Löwenstein-Jensen
solid medium. We used an extended panel of biochemical and
cultural tests for conventional identification. On the basis of
these test results, the most likely identification, estimated by a
program for the computerized identification of mycobacteria
(19), appeared to be M. avium-intracellulare (Table). All strains
isolated from this patient produced a weak yellow pigment in
the dark, which grew at 45°C and were negative for arylsulfa-
tase activity when tested after 3 days by the method of Kubica
and Rigdon (20). The Bactec NAP test (Becton Dickinson
Biosciences) did not demonstrate, as expected, any inhibition
by para-nitro-α-acetilamino-β-hydroxypropiophenone (NAP).
The hybridization test performed with Accuprobe specific for
MAC gave negative results. Weak positive or slightly below
the cutoff (30,000 RLUs) results were observed with
Accuprobe MTB (mean RLU value 51,170; range
28,219–111,365). When selection reagent (unbound probe
hydrolysis) incubation time was set at 10 min, M. celatum
strains clearly showed negative results (range 5,721–9,574;
mean RLU value 7,210). A reference strain (M. tuberculosis
ATCC 25177), run in the hybridization assay as a positive con-
trol, gave RLUs of 580,321, about 20 times the cut-off value.
Finally, the strains were sent to the Mycobacteria Reference
Centre in Florence, Italy (Dr. E. Tortoli), and studied by HPLC
analysis of mycolic acids. They showed the same profile that
allowed all of our strains to be attributed to M. celatum.
MICs (µg/mL) determined for the first isolate were the fol-
lowing: streptomycin, 2.0; isoniazid, 0.5; rifampin, >64.0;
ethambutol, 2.5; ciprofloxacin, 1.0; ofloxacin, 1.0; clar-
ithromycin, 1.0; ethionamide, 2.5; and rifabutin, 0.5. Drug sus-
ceptibility testing was completed after 6 days. 
We searched the English-language literature from 1993 to
2001 for all previously reported cases of pulmonary infections
with M. celatum in immunocompetent patients. The search yield-
ed two published reports (12,13). Descriptions of the clinical
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Figure. Chest x-ray showing nodular lesions and lung cavitation before
(A) and after (B) treatment.
Table. Biochemical analysis of the described isolate (Mycobacterium 
celatum) compared to those of M. avium complex and M. xenopi 
Results
a for: 
Characteristics  Our isolate 
M. avium 
complex  M. xenopi 
Niacin  –  –  – 
Nitrate reduction  –  –  – 
Thermostable catalase  +  +  + 
Tween 80 hydrolysis (10 days)  –  –  – 
Tellurite reduction  +  +  V 
Arylsulfatase (3 days)  –  –  + 
Urease  –  –  – 
Catalase (over 45 mm of foam)  –  –  – 
Photochromogenicity  –  –  – 
Scotochromogenicity  +  –  + 
Growth at 25°C  +  +  – 
Growth at 37°C  +  +  + 
Growth at 45°C  +  –  + 
MacConkey w/o CV  –  –  – 
Tolerance to NaCl (5%)  –  –  – 
Tolerance to TCH (5 mg/mL)  +  +  + 
Growth rate  Slow  Slow  Slow 
Colonial morphologic features  Smooth  Smooth  Smooth 
a– negative; +, positive; v, variable; TCH, thiophene-2-carboxylic acid hydrazide. signs, radiologic findings, and treatment were not always avail-
able, however.
Clinical and radiographic features of M. celatum pul-
monary infection resemble those of tuberculosis and other non-
tuberculous mycobacterial infections. Cough and weight loss
are the main symptoms, while pulmonary infiltrates and exten-
sive cavitations have been described in all published reports.
Patients did not suffer from any underlying diseases when pul-
monary infection with M. celatum was diagnosed and had a
strongly positive tuberculin skin test, suggesting immunocom-
petence. Published data and our findings indicate that M. cela-
tum caused pulmonary disease, and not merely colonization, in
the affected patients. Indeed, all of these cases met the
American Thoracic Society criteria for the diagnosis of nontu-
berculous mycobacterial disease. The patients displayed radi-
ographic evidence of pulmonary disease that could not be
attributed to other causes and that was associated in two of
three cases with the repeated isolation of the same mycobacte-
rial strain. By contrast, clinical presentation in immunocompro-
mised patients differs greatly, being characterized by interstitial
pulmonary infiltrates or by clinical and micobiologic evidence
of disseminated disease (7).
M. celatum strains were isolated on currently used liquid
media in all reported cases (radiometric Bactec 12B and
MB/BacT [Organon Teknika B.V., Boxtel, the Netherlands]),
while samples from one of the published case-patients did not
grow on conventional Löwenstein-Jensen solid medium, and
growth has not been reported for samples from the second case-
patient. Data from an extended panel of biochemical and cul-
tural tests for conventional identification have not been report-
ed; however, the appearance of a scotochromogenic pale yel-
low pigment with growth at 45°C and a negative 3-day arylsul-
fatase test are in full agreement with our present and previous
findings (7). All strains showed a partial hybridization with
Accuprobe MTB, which disappeared after 10 min of incubation
with selection reagent. From a practical standpoint, setting the
selection time at 10 min is advisable when the Accuprobe iden-
tification is performed on a mycobacterial culture grown in a
liquid medium. In this situation, the characteristics of
mycobacterial colonies cannot be observed and false-positive
reactions may lead to misidentification. However, if the
Accuprobe assay is carried out on a mycobacterial culture
grown on a solid medium, a 5-min selection time is recom-
mended. In this case, the appearance of mycobacterial colonies
and their characteristics of growth may help to evaluate
Accuprobe results. Thus, a weak positive reaction when testing
nontuberculous mycobacteria with the M. tuberculosis complex
Accuprobe strongly suggests that the organism is likely to be
M. celatum. 
In one case (13), a misleading positive reaction occurred
when a clinical sample containing M. celatum was tested for
MTB by the Amplified M. tuberculosis direct test (AMTD,
Gen-Probe, Inc.). The test amplifies 16S rRNA of
Mycobacterium species by transcription-mediated amplifica-
tion (21). The resulting amplicons are then detected by a
hybridization protection assay by using a probe that targets the
same genomic region as the probe of the Accuprobe kit (22). In
our case, when we tested clinical samples by a different ampli-
fication system, no false-positive results potentially leading to
a delay of appropriate treatment were reported. Patients
(including our case-patient) were given different treatment reg-
imens, with three or four antibiotics, mainly ethambutol,
rifabutin, clarithromycin, and ciprofloxacin. Clinical improve-
ment, as defined by resolution of symptoms and improved radi-
ographic findings (infiltrates and cavitary lesions), was
obtained within 6 months after initiation of therapy in two of
three patients. One patient who received antimycobacterial
therapy died 10 weeks after admission from complications
apparently related to the M. celatum infection (12). Data from
necropsy were not reported. Both cured patients showed a
marked improvement when clarithromycin was added the
chemotherapy regimen; the patient who later died felt better for
3 weeks when his chemotherapy was changed to a new sched-
ule that included clarithromycin. Despite evidence of clinical
and radiologic improvement, one patient was still sputum-pos-
itive 1 year after the initiation of therapy (13). In-vitro suscep-
tibility data (when available) seemed to correlate with patients’
clinical improvement as the MICs of tested drugs were below
the serum concentrations achievable during therapy.
Our findings show that M. celatum is an infrequent cause
of potentially treatable pulmonary disease in immunocompe-
tent subjects. Clinical picture and repeated isolation from respi-
ratory specimens enabled us to consider M. celatum strains as
clinically relevant in all the patients reported. Treatment with a
three- or four-drug combination, including clarithromycin and
ethambutol, should result in considerable reduction in the ill-
ness associated with this disease. Although at present only 16S
rDNA sequencing or mycolic acid HPLC analysis can confirm
M. celatum identification, the most practical way to get a pre-
liminary identification relies on a positive DNA hybridization
signal for MTB at 5 min but negative hybridization at 10 min
with the Accuprobe test. Finally, although no major immuno-
logic disorder could be detected in these patients, the host’s
defense failure associated with M. celatum infection suggests a
possible “hidden immunodeficiency” rather than a true
immunocompetence. Recent data on the immunology of nontu-
berculous mycobacterial infections (23) seem to support this
hypothesis.
Dr. Piersimoni is a clinical microbiology consultant at the
Umberto I°–Torrette Hospital in Ancona, Italy. His primary research
interests focus on epidemiologic and clinical aspects of mycobacterial
infections.
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